Abstract:AI is expected to help identify excellent candidates in drug discovery. However, we face a lack of data as it is time consuming and expensive to acquire raw data perfectly for many compounds. Hence, we tried to develop a novel QSAR method to predict a parameter more precisely from an incomplete dataset via optimizing data handling by making use of predicted explanatory variables. As a case study we focused on the tissue-to-plasma partition coefficient (Kp), which is an important parameter for understanding drug distribution in tissues and building the physiologically based pharmacokinetic (PBPK) model, is a representative of small and sparse datasets. In this study, we predicted the Kp values of 119 compounds in nine tissues (adipose, brain, gut, heart, kidney, liver, lung, muscle, and skin), while some of these were not available. To fill the missing values in Kp for each tissue, firstly we predicted those Kp values by the non-missing dataset using a random forest (RF) model with in vitro parameters (log P, fu, Drug Class, and fi) like a classical prediction by a QSAR model. Next, to predict the tissue-specific Kp values in a test dataset, we constructed a second RF model with not only in vitro parameters but also the Kp values of other tissues (i.e. other than target tissues) predicted by the first RF model as explanatory variables. Furthermore, we tested all possible combinations of explanatory variables and selected the model with the highest predictability from the test dataset as the final model. The evaluation of Kp prediction accuracy based on the root-mean-square error and R2-value revealed that the proposed models outperformed other machine learning methods, such as the conventional RF and message-passing neural networks. Significant improvements were observed in the Kp values of adipose tissue, brain, kidney, liver, and skin. These improvements indicated that the Kp information of other tissues can be used to predict the same for a specific tissue. Additionally, we found a novel relationship between each tissue by evaluating all combinations of explanatory variables. In conclusion, we developed a novel RF model to predict Kp values. We hope that this method will be applied to various problems in the field of experimental biology which often contains missing values in the near future.

Investigating pharmacokinetic profiles of Centella asiatica using machine learning and PBPK modelling

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

In Silico Modeling on ADME Properties of Natural Products: Classification Models for Blood-Brain Barrier Permeability, Its Application to Traditional Chinese Medicine and in Vitro Experimental Validation

PBPK Model and Its Application in TCM Studies

Predicting Pharmacokinetics of Active Constituents in Spatholobi caulis by Using Physiologically Based Pharmacokinetic Models

Predicting pharmacodynamic effects through early drug discovery with artificial intelligence-physiologically based pharmacokinetic (AI-PBPK) modelling

PBPK modeling and simulation in drug research and development

A Combination of Machine Learning and PBPK Modeling Approach for Pharmacokinetics Prediction of Small Molecules in Humans

Utilization of Physiologically Based Pharmacokinetic Modeling in Pharmacokinetic Study of Natural Medicine: An Overview

Prediction of physicochemical and pharmacokinetic properties of botanical constituents by computational models

A review of pharmacokinetic and pharmacological properties of asiaticoside, a major active constituent of Centella asiatica (L.) Urb.

Adapting physiologically-based pharmacokinetic models for machine learning applications

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach

Biotechnological Intervention and Secondary Metabolite Production in Centella asiatica L.

Application of Physiologically Based Pharmacokinetic Modeling in Preclinical Studies: A Feasible Strategy to Practice the Principles of 3Rs

Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds

Development of Novel Methods for QSAR Modeling by Machine Learning Repeatedly: A Case Study on Drug Distribution to Each Tissue

Predictive Modelling in pharmacokinetics: from in-silico simulations to personalized medicine

Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery

Systematic Evaluation of High-Throughput PBK Modelling Strategies for the Prediction of Intravenous and Oral Pharmacokinetics in Humans

Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective